Recognizing AD Across All Skin Tones
August 28th 2025Panelists discuss how atopic dermatitis (AD) presents differently across skin tones, appearing as purple, gray, or barely visible inflammation rather than classic redness, with perifollicular prominence and postinflammatory pigmentation changes being more prominent in patients with darker skin.
Beyond the Itch: The Full Spectrum of AD Symptoms and Their Impact on Patients
August 28th 2025Panelists discuss how atopic dermatitis (AD) extends far beyond pruritus to include pain, sleep disturbances, psychosocial stigma, and quality-of-life impacts that affect patients’ work, school, and daily functioning regardless of disease severity.
Efficient Strategies to Reduce Wait Time Between Diagnosis of Hidradenitis Suppurativa and Treatment
August 22nd 2025Panelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like step therapy, emphasizing the need for patient education, strategic planning, and leveraging resources—including clinical trials—to improve timely treatment and outcomes.
Preparing for Updates to Hidradenitis Suppurativa Guidelines
August 22nd 2025Panelists discuss the anticipated 2026 updates to the American Academy of Dermatology guidelines for hidradenitis suppurativa, highlighting efforts to unify treatment protocols, support biologic access, and accommodate emerging therapies within a rapidly evolving therapeutic landscape.
Bridging the Gaps: Health Care Professional Knowledge Gaps in AD Pathophysiology
August 21st 2025Panelists discuss how health care professionals face educational gaps in understanding atopic dermatitis (AD) immunopathogenesis, with advanced practice providers (APPS) particularly needing additional training outside standard curricula to master biologic therapy selection.
The Window of Opportunity: Why Early Biologic Use Matters for Patients With Hidradenitis Suppurativa
August 15th 2025Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and systemic barriers that delay timely treatment and worsen patient outcomes.
Navigating Access and Coverage Hurdles: Step Therapy in Hidradenitis Suppurativa
August 15th 2025Panelists discuss the challenges and evolving landscape of step therapy protocols in hidradenitis suppurativa treatment, emphasizing the impact on patient adherence, the potential benefits of earlier biologic use, and the need for advocacy to improve access and outcomes.
The Role of Biologics for Treatment of Hidradenitis Suppurativa
August 8th 2025Panelists discuss the timely initiation of biologic therapy in moderate to severe hidradenitis suppurativa, emphasizing individualized treatment decisions based on disease impact and quality of life, alongside the potential for improved outcomes and cost-effectiveness through early, aggressive management.
Building Hidradenitis Suppurativa Treatment Plan: Evaluating Standard of Care Pharmacotherapies
August 1st 2025Panelists discuss the importance of coordinated, personalized treatment strategies for hidradenitis suppurativa, highlighting early use of pharmacologic therapies—including biologics—and ongoing assessment to balance clinical effectiveness, patient quality of life, and financial considerations.
Proactive Hidradenitis Suppurativa Management: From Watchful Waiting to Active Intervention
August 1st 2025Panelists discuss optimizing hidradenitis suppurativa management through early intervention, personalized treatment based on disease severity, and multidisciplinary coordination led by dermatologists to improve patient outcomes and reduce disease burden.
Health Equity in Hidradenitis Suppurativa: Addressing Care Disparities
July 25th 2025Panelists discuss the significant disparities in hidradenitis suppurativa diagnosis and care, emphasizing the impact of race, gender, geography, and socioeconomic status, and highlighting the need for culturally competent education, expanded access, and community engagement to promote earlier intervention and equitable outcomes.
The Pharmacist Advantage: Bridging Gaps in Hidradenitis Suppurativa Care
July 25th 2025Panelists discuss the vital role of multidisciplinary collaboration, provider education, and technology integration in improving early diagnosis and comprehensive management of hidradenitis suppurativa, highlighting how coordinated efforts across specialties—including pharmacists—can reduce delays, enhance equity, and optimize patient outcomes.
Hidden in Plain Sight: Strategies to Improve Early Identification of Hidradenitis Suppurativa
July 18th 2025Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for provider education, clinical decision support, and multidisciplinary collaboration to promote earlier recognition and more effective, coordinated care.
Recognizing Hidradenitis Suppurativa: From First Signs to an Accurate Diagnosis
July 18th 2025Panelists discuss the challenges of timely diagnosis and comprehensive management of hidradenitis suppurativa, emphasizing the need for early recognition, multidisciplinary care, and empathy-centered approaches to address the physical, emotional, and social burden of the disease.